D. E. Shaw & Co., Inc. Acadia Pharmaceuticals Inc Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 3,504,957 shares of ACAD stock, worth $58.5 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

3,504,957

Holding current value

$58.5 Million

% of portfolio

0.05%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$15.14 - $19.14 $8.63 Million - $10.9 Million	570,031 Added 19.42%	3,504,957 $53.9 Million
Q2 2024 Aug 14, 2024	BUY	$14.62 - $18.42 $4.28 Million - $5.4 Million	292,906 Added 11.09%	2,934,926 $47.7 Million
Q1 2024 May 15, 2024	SELL	$17.79 - $30.86 $19.8 Million - $34.3 Million	-1,112,578 Reduced 29.63%	2,642,020 $48.9 Million
Q4 2023 Feb 14, 2024	SELL	$20.78 - $31.77 $21.5 Million - $32.9 Million	-1,034,400 Reduced 21.6%	3,754,598 $118 Million
Q3 2023 Nov 14, 2023	SELL	$20.84 - $33.47 $9.88 Million - $15.9 Million	-474,080 Reduced 9.01%	4,788,998 $99.8 Million
Q2 2023 Aug 14, 2023	BUY	$17.8 - $25.65 $6.45 Million - $9.3 Million	362,496 Added 7.4%	5,263,078 $126 Million
Q1 2023 May 15, 2023	BUY	$16.32 - $20.92 $11.1 Million - $14.3 Million	681,183 Added 16.14%	4,900,582 $92.2 Million
Q4 2022 Feb 14, 2023	SELL	$14.2 - $18.63 $7 Million - $9.18 Million	-492,781 Reduced 10.46%	4,219,399 $67.2 Million
Q3 2022 Nov 14, 2022	BUY	$14.11 - $18.27 $360,016 - $466,159	25,515 Added 0.54%	4,712,180 $77.1 Million
Q2 2022 Aug 15, 2022	BUY	$13.01 - $27.22 $1.82 Million - $3.8 Million	139,702 Added 3.07%	4,686,665 $66 Million
Q1 2022 May 16, 2022	BUY	$20.94 - $27.5 $413,774 - $543,400	19,760 Added 0.44%	4,546,963 $110 Million
Q4 2021 Feb 14, 2022	SELL	$16.79 - $27.09 $17.5 Million - $28.3 Million	-1,043,329 Reduced 18.73%	4,527,203 $106 Million
Q3 2021 Nov 15, 2021	BUY	$15.78 - $24.77 $12.7 Million - $20 Million	805,467 Added 16.9%	5,570,532 $92.5 Million
Q2 2021 Aug 16, 2021	BUY	$19.4 - $27.42 $46.8 Million - $66.1 Million	2,409,857 Added 102.32%	4,765,065 $116 Million
Q1 2021 May 17, 2021	BUY	$25.02 - $54.99 $2.81 Million - $6.18 Million	112,408 Added 5.01%	2,355,208 $60.8 Million
Q4 2020 Feb 16, 2021	SELL	$41.04 - $56.79 $891,101 - $1.23 Million	-21,713 Reduced 0.96%	2,242,800 $120 Million
Q3 2020 Nov 16, 2020	BUY	$36.42 - $57.0 $4.24 Million - $6.63 Million	116,305 Added 5.41%	2,264,513 $93.4 Million
Q2 2020 Aug 14, 2020	BUY	$39.26 - $52.73 $33.7 Million - $45.2 Million	858,079 Added 66.51%	2,148,208 $104 Million
Q1 2020 May 15, 2020	SELL	$31.65 - $46.87 $2.75 Million - $4.08 Million	-86,965 Reduced 6.32%	1,290,129 $54.5 Million
Q4 2019 Feb 14, 2020	SELL	$36.21 - $51.4 $32.4 Million - $46 Million	-895,290 Reduced 39.4%	1,377,094 $58.9 Million
Q3 2019 Nov 14, 2019	BUY	$22.22 - $44.01 $8.23 Million - $16.3 Million	370,534 Added 19.48%	2,272,384 $81.8 Million
Q2 2019 Aug 14, 2019	BUY	$23.32 - $28.12 $10.8 Million - $13 Million	461,869 Added 32.07%	1,901,850 $50.8 Million
Q1 2019 May 15, 2019	BUY	$16.17 - $27.38 $20.9 Million - $35.3 Million	1,290,639 Added 864.22%	1,439,981 $38.7 Million
Q4 2018 Feb 14, 2019	BUY	$14.32 - $22.92 $2.14 Million - $3.42 Million	149,342 New	149,342 $2.42 Million
Q3 2018 Nov 14, 2018	SELL	$13.03 - $21.81 $733,159 - $1.23 Million	-56,267 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$15.07 - $22.34 $570,218 - $845,300	37,838 Added 205.32%	56,267 $859,000
Q3 2017 Nov 14, 2017	BUY	$29.49 - $38.37 $543,471 - $707,120	18,429	18,429 $694,000

Others Institutions Holding ACAD

# of Institutions

279

Shares Held

156M

Call Options Held

901K

Put Options Held

314K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.7B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account